title: Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor.
abstract: BACKGROUND
  Cyclin-dependent kinases (CDKs) are involved in the regulation of the cell cycle and the growth of tumor cells. In this study, we investigated the antitumor effect and differentially expressed genes (DEGs) in head and neck cancer cells treated by a novel CDK inhibitor, 2-[1,1'-biphenyl]- 4-yl-N-[5-(1,1-dioxo-1lambda(6)-isothiazolidin-2-yl)-1H-indazol-3-yl] acetamide (BAI).
  
  
  METHODS
  Cell growth was measured by XTT assay. Cell cycle and apoptosis were determined using flow cytometry. GeneFishing PCR was utilized to identify DEGs. Protein expression was analyzed by Western blot.
  
  
  RESULTS
  Exposure to BAI of 2 different head and neck cancer cell lines, AMC-HN4 and AMC-HN6, induced apoptosis in association with growth inhibition, cell cycle arrest, caspase-3 activation and cytochrome c release. Significantly, data from GeneFishing PCR experiments demonstrated 10 DEGs in AMC-HN6 cells treated with BAI. Some of these DEGs turned out to encode proteins with functions related to key cellular processes.
  
  
  CONCLUSIONS
  These results indicate that BAI has strong anticancer activities on head and neck cancer cells, and the DEGs induced by BAI may become involved in BAI-induced cancer cell death.
authors: Department of Otolaryngology, Keimyung University, Daegu, South Korea.
authors: Ho Cheol
authors: HC
authors: Shin
authors: Dal Won
authors: DW
authors: Song
authors: Won Ki
authors: WK
authors: Baek
authors: Seong Ryong
authors: SR
authors: Lee
authors: Taeg Kyu
authors: TK
authors: Kwon
authors: Jinho
authors: J
authors: Lee
authors: Sol Hee
authors: SH
authors: Park
authors: Byeong-Churl
authors: BC
authors: Jang
authors: Jong-Wook
authors: JW
authors: Park
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D045304:Cytochromes c / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D052138:Genes, Neoplasm / Q000187:drug effects; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007191:Indazoles / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D053778:Thiazolidines / Q000494:pharmacology*; D010738:Type C Phospholipases / Q000378:metabolism
chemical_list: C545562:2-(1,1'-biphenyl)-4-yl-N-(5-(1,1-dioxo-1lambda(6)-isothiazolidin-2-yl)-1H-indazol-3-yl)acetamide; D000970:Antineoplastic Agents; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D053778:Thiazolidines; D045304:Cytochromes c; D018844:Cyclin-Dependent Kinases; D010738:Type C Phospholipases; D053148:Caspase 3